USA News Group – How we deal with future spikes in disease cases and potential global pandemics is evolving rapidly. Not only is the World Economic Forum championing more ...

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential for ...

January 2025 – LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading Pharmaceutical technology company, is proud to announces ...

ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG (LTS), a leading <a target=_blank href= ...

The Biden administration is releasing a “roadmap” for maintaining government defenses against infectious diseases, just as ...

全球视野下，一家中国Biotech正在穿越行业寒冬和击碎不确定性，不仅深耕于全球最前沿肿瘤治疗领域mRNA技术平台与管线的开发，同时也在肾科等未满足临床需求适应症领域前瞻性落子，深挖全球蓝海赛道背后的巨大差异化机会。

【导读】用于信使核糖核酸（mRNA）递送的脂质纳米颗粒（LNPs）已取得显著进展，但脂质纳米颗粒介导的脱氧核糖核酸（DNA）递送在临床上仍面临诸多挑战。1月13日，美国贝勒医学院研究人员在期刊《Molecular Cancer》上发表了研究论文，题为 ...

Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare ...

PopVax awarded $2M for its patch-delivered mRNA influenza vaccine in collaboration with LTS Lohmann as part of BARDA’s Patch Forward Prize.

Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for infectious disease prevention and continue to be utilized across various fields.

Vancouver-based Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and an expansive lipid ...